Insight Molecular Diagnostics
IMDX
41 hedge funds and large institutions have $20.3M invested in Insight Molecular Diagnostics in 2017 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 5 closing their positions.
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
24% more funds holding
Funds holding: 33 → 41 (+8)
0.02% more ownership
Funds ownership: 0.64% → 0.66% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less capital invested
Capital invested by funds: $22.5M → $20.3M (-$2.18M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$661K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$232K |
| 3 |
New York State Common Retirement Fund
Albany,
New York
|
+$89.4K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$62K |
| 5 |
Citigroup
New York
|
+$56.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$500K |
| 2 |
Millennium Management
New York
|
-$157K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$74K |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$22.8K |
| 5 |
Barclays
London,
United Kingdom
|
-$6.03K |
IMDX Hedge Fund Activity: Q2 2017 in Review
41 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q2 2017, worth a combined $20.3M — down 9.7% from $22.5M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new IMDX positions and 5 closed out — a net gain of 8 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was BlackRock, adding an estimated $661K. The largest seller was Manatuck Hill Partners, exiting entirely with an estimated $500K sold.
- 41 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q2 2017, up from 33 in Q1 2017.
- Funds reported $20.3M of Insight Molecular Diagnostics stock for Q2 2017, down 9.7% quarter-over-quarter.
- 13 funds opened new Insight Molecular Diagnostics positions in Q2 2017 and 5 closed out, a net change of +8 holders.
- The largest Insight Molecular Diagnostics buyer in Q2 2017 was BlackRock, an estimated $661K added.
- The largest Insight Molecular Diagnostics seller in Q2 2017 was Manatuck Hill Partners, an estimated $500K sold.
Based on aggregated 13F filings for Q2 2017.